Gestational Diabetes
Conditions
Keywords
Gestational Diabetes, Serum amyloid A, Interleukin-1 (IL-1) receptor antagonist
Brief summary
Serum amyloid A and Interleukin-1 (IL-1) receptor antagonist (A-SAA and IL-1Ra) values; * Comparison of pregnant women with and without GDM diagnosis * Comparison of insulin therapy and diet-regulated GDM patients * Comparison of pregnant women with and without LGA (large gestational age) * Comparison of pregnant women with and without polyhydroamnios * Investigation of its effect on pregnancy prognosis * In the prediction of GDM diagnosis, it is aimed to study the sensitivity and specificity of both parameters and cut off values. (In GDM patients, liver and kidney function parameters will also be evaluated with A-SAA and IL-1Ra levels).
Interventions
DIAGNOSTIC_TESTSerum amyloid A values
Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
DIAGNOSTIC_TESTInterleukin-1 (IL-1) receptor antagonist values (A-SAA and IL-1Ra)
Women who are diagnosed with GDM between the ages of 18 and 43 will receive blood in the biochemistry tube. This tube will then be centrifuged. A-SAA and IL-1Ra levels will be checked by ELISA method in serum stored at -80 degrees.
Sponsors
Kanuni Sultan Suleyman Training and Research Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 42 Years
Healthy volunteers
Yes
Inclusion criteria
* Patients with 50 gr OGTT + 100 gr OGTT + at 24-28 weeks of gestation * Patients with 75 gr OGTT + at 24-28 weeks of gestation * 18-42 years pregnant women
Exclusion criteria
* any infection * Any known fetal chromosomal or structural anomaly * Preterm membrane rupture * Preterm delivery * Preeclampsia or eclampsia * Placenta previa
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum amyloid A | 1 week | Its level will be checked in the study group consisting of pregnant women with GDM and in the control group consisting of healthy pregnant women. |
| Interleukin-1 (IL-1) receptor antagonist | 1 week | Its level will be checked in the study group consisting of pregnant women with GDM and in the control group consisting of healthy pregnant women. |
Countries
Turkey (Türkiye)
Outcome results
None listed